Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention

Author(s): Ali Ali, Pierluigi Costanzo, Angela Hoye*.

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 4 , 2018


Abstract:

Elevated levels of Low Density Lipoprotein cholesterol (LDL-C) are directly associated with increased risk for atherosclerotic cardiovascular and cerebrovascular events. Statins have been used to control serum LDLC and this has translated into reduction in cardiovascular and cerebrovascular events. However, despite high dose statin therapy, LDL-C control may remain inadequate in some patients, particularly those with familial hypercholesterolemia. A new therapeutic approach has emerged in recent years with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.

In this review, we describe the development and the use of this new class of drugs.

Keywords: Cholesterol, LDL, PCSK9 inhibitors, statins, serum LDL-C, hypercholesterolemia.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 24
ISSUE: 4
Year: 2018
Page: [442 - 450]
Pages: 9
DOI: 10.2174/1381612824666180111105201
Price: $58

Article Metrics

PDF: 20
HTML: 3
EPUB: 1
PRC: 1

Special-new-year-discount